Drug Trial Radar · NCT01732926
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
475
Actual
Start
Jan 2, 2013
Primary completion
May 17, 2016
Study completion May 17, 2016
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL). An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).
Conditions
- Indolent Non-Hodgkin's Lymphomas
Interventions
IdelalisibDrug
150 mg tablet administered orally twice daily
RituximabDrug
375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
BendamustineDrug
90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
PlaceboDrug
Tablet administered orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)
Locations
144 sites in 15 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama
Ironwood Cancer and Research Center
Chandler, Arizona
Comprehensive Blood and Cancer Center (Bakersfield)
Bakersfield, California
Saint Jude Heritage Healthcare (TORI)
Fullerton, California
Pacific Shores Medical Group
Long Beach, California
Cancer Care Associates
Redondo Beach, California
San Luis Obispo Oncology and Hematology
San Luis Obispo, California
Cancer Center of Santa Barbara
Santa Barbara, California
Central Coast Medical Oncology Group
Santa Maria, California
St Joseph Heritage Healthcare System
Santa Rosa, California
Kaiser Permanente Vallejo Medical Center
Vallejo, California
Sylvester Comprehensive Cancer Center/UMHC
Deerfield Beach, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Northwest Georgia Oncology Centers, PC
Marietta, Georgia
Rush University Medical Center
Chicago, Illinois
Joliet Oncology Hematology Associates Ltd.
Joliet, Illinois
Cancer Center of Kansas
Wichita, Kansas
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
North Shore Hematology/Oncology Associates
East Setauket, New York
Weill Cornell Medical College
New York, New York
Signal Point Clinical Research Center, LLC
Middletown, Ohio
Hollings Cancer Center
Charleston, South Carolina
Bon Secours Saint Francis Hospital
Greenville, South Carolina
Texas Oncology, P.A.
Bedford, Texas
Charles A. Sammons Cancer Center
Dallas, Texas
Texas Oncology, P.A.
Denton, Texas
Brooke Army Medical Center
Fort Sam Houston, Texas
Texas Oncology, P.A.
Harlingen, Texas
Texas Oncology, P.A.
Weslaco, Texas
Swedish Medical Center
Seattle, Washington
Northwest Medical Specialists
Tacoma, Washington
Aurora BayCare Medical Center
Green Bay, Wisconsin
Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin
Prince of Wales Hospital
Randwick, New South Wales, Australia
Haematology and Oncology Clinics of Australia Gold Coast
South Brisbane, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Adelaide Cancer Centre
Kurralta Park, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Saint Vincent's Hospital
Fitzroy, Victoria, Australia
Showing 40 of 144 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.